Five things to know:
1. Quarterly revenue rose 2.5% year over year, according to a news release.
2. Medtronic’s neuroscience portfolio, which includes cranial and spinal technologies, saw a 4.4% year-over-year increase in revenue with $2.5 billion.
3. Cranial and spinal technologies saw $1.25 billion in sales, a 3.8% increase year over year. Growth was driven by adoption of the AiBLE ecosystem of enabling technologies.
4. Neuromodulation sales were $476 million, a 12% year-over-year increase.
5. Medtronic expects its fiscal year 2025 revenue to grow between 4.75% to 5% year over year.
